("MaxCyte" or the "Company")
Notice of Annual General Meeting
Change of Director
Gaithersburg, Maryland - 1 October 2021: MaxCyte, Inc (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, announces that formal notice and resolutions of the Company's Annual General Meeting (AGM), have been circulated to Shareholders.
These documents are also available in electronic form on the Company's website: www.maxcyte.com.
In addition, on September 30, 2021, Dr. J. Stark Thompson notified the board of directors (the "Board") of the Company that he will not stand for re-election at the Annual Meeting of Stockholders to be held on October 29, 2021 (the "Annual Meeting"). Dr. Thompson will serve out his remaining term as a director and as Chairman of the Board, which will expire upon the conclusion of the Annual Meeting. Dr. Thompson's decision is not related to any disagreement relating to the Company's operations, policies or practices. He will continue to provide consulting services to the Company as requested, during which time his outstanding stock option awards will continue to vest in accordance with their terms for so long as Dr. Thompson provides continuous service to the Company. Following the Annual Meeting, the authorized size of the Board will be eight members, and the Board will appoint a new Chairman.
"On behalf of the Board and the entire MaxCyte team, we wish to thank Dr. Thompson for his service and guidance on the Board over the years," said Doug Doerfler, Chief Executive Officer.
For further information, please contact:
US IR Adviser
David Deuchler, CFA
Nominated Adviser and Joint Corporate Broker
Emma Earl / Freddy Crossley
+44 (0)20 7886 2500
UK IR Adviser
Consilium Strategic Communications
+44 (0)203 709 5700
| || |
MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: three instruments, the ATx™, STx™ and GTx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.